I N T R O D U C T I O N
Antibacterial drug discovery research, accompanied by clinical development, has historically been conducted by large pharmaceutical companies. Although the earliest antibiotics were first identified in academic laboratories such as those of Alexander Fleming (penicillin) [1] and Selman Waksman (streptomycin) [2] , pharmaceutical companies were responsible for successful strain optimisation, compound scale-up, formulation and clinical development activities that allowed anti-infective drug research to gain prominence as a viable area for corporate investment. After the successful commercialisation of penicillin following the Second World War, companies like Abbott, Beecham, Bristol, Glaxo, Lederle, Lilly, Merck, Pfizer, Roche, Schering and Squibb became leaders in antibiotic development and maintained active antibacterial research organisations for decades.
Although many of the former corporate leaders have recently scaled back their efforts in this area, antibacterial drug discovery remains an important opportunity for at least some of the pharmaceutical sector. In this article, four major reasons to support the continuation of antibacterial drug discovery are provided: medical needs based on the continued increase in resistant pathogens, development advantages, commercial viability, and social factors.
M E D I C A L N E E D Resistance
Soon after each antibacterial agent entered into clinical practice, resistance was reported in at least one bacterial pathogen (Table 1) . Because the first antibiotics, excluding the synthetic sulfa drugs, were all identified or derived from natural products, resistance determinants had already accumulated in the environments from which these agents originated. It was only a short period of time before selection pressures allowed these environmental resistance determinants to become incorporated into the pathogenic bacteria that were being treated with the new antibiotics.
Selection of resistant strains occurred so quickly for some bacteria-antibiotic combinations that clinical utility of the antibiotic was severely diminished within a 5-year time span. The first documented example of the rapid selection of a resistant population was the increase in penicillin resistance from £8% to almost 60% in Staphylococcus aureus from 1945 to 1949 ( Fig. 1 ). In many cases, chromosomal mutations led to class resistances to other closely related agents, allowing for the emergence of clonal strains when subjected to antibiotic pressures. Examples of chromosomal mutations leading to class resistances include topoisomerase mutations selected by nalidixic acid and later fluroroquinolones, and selection of derepressed AmpC b-lactamases by any of a number of second and third generation cephalosporins. Of perhaps even graver consequence are the plasmid-mediated resistances, whereby a resistant strain selected by one antibiotic can result in resistance to other antibiotic classes due to the presence of multiple resistance determinants in the same operon. Most importantly, these plasmids can be transferred among species, resulting in multifactorial resistance in organisms such as Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
Following the identification of resistance to a class or to a specific agent, the pharmaceutical industry has responded with new generations or new classes of drugs ( Table 2) . Examples of these were the development of the 'penicillinase-stable penicillins' to counteract Gram-positive b-lactamases, second generation aminoglycosides to avoid streptomycin resistance, third generation cephalosporins to provide improved activity against Gram-negative pathogens, the ketolide telithromycin to avoid macrolide resistance in the pneumococci, and linezolid in a novel class of synthetic oxazolidinones with no cross-resistance to any known antibiotic class. However, in all cases, resistance has emerged to the new agents, thus repeating the cycle (Table 1) .
At this time in the history of the antibiotic world, one might imagine that all resistance mechanisms could be overcome by at least some agent. Indeed, some have stated that virtually all infections can be treated by at least a combination of effective drugs, so it is not necessary to develop new agents. Unfortunately, that is not the case, as evidenced by the multidrug-resistant enteric bacteria, and the pan-resistant pseudomonads that [11, 12] a Assumed to be resistance mechanism. Not identified at time of report. Year % Penicillinase-producing S. aureus Fig. 1 . Rapid increase in penicillinase production in S. aureus [13, 14] .
are currently being treated with the toxic membrane-disruptive polymyxins [15] .
With the approval of the three most recent antibacterial agents, linezolid in 2000, daptomycin in 2003 and telithromycin in 2002-04, three new classes of agents have been introduced into the marketplace. However, as might be expected, resistance has already been reported for all three agents, thus providing an opportunity for additional agents in these classes to overcome the new resistances identified.
Unmet needs and resistance
Why, or when, does a research organisation make the decision to develop a new drug to counteract resistance? A major factor must be unmet medical need. This need is closely tied to the rapidity and proliferation of resistance development, and the number of other drugs that may be used for the same therapeutic indication. One can cite the recent flurry of activity to develop drugs to treat multidrug resistant (MDR) Grampositive bacteria, including MRSA (methicillinresistant Staphylococcus aureus) and VRE (vancomycin-resistant enterococci). With the increasing threats from less resistant but more virulent community-acquired MRSA strains [16] , it should be expected that orally active agents other than b-lactams will be of high interest. As indicated by Livermore in this supplement [17] , other medical needs may be met with new agents to treat infections caused by MDR pathogens such as, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Acinetobacter spp., Enterococcus faecium, MDR enterobacteriaceae and MDR Mycobacterium tuberculosis. All but MDR M. tuberculosis are usually associated with hospital infections, thus indicating that drugs in the hospital market will continue to provide opportunities to meet increased medical needs.
Emerging diseases
As we try to predict the future needs in infectious diseases, there are always going to be unpredictable factors such as the appearance of new diseases, or the newly recognised association of established diseases with infectious agents. Examples of previously unrecognised infectious diseases are Legionnaire's disease that was found to be associated with Legionella pneumophila [18] , and multiple viral diseases such as ebola, AIDS, hepatitis C and SARS. Diseases described before they were known to be caused by infectious agents include cat scratch disease caused by Bartonella henselae [19] , and gastric ulcers caused by Helicobacter pylori [20] . In addition, diseases that were once thought to be under control by existing therapies may re-emerge, such as cholera, dengue and pertussis.
As with the case of H. pylori and ulcers, there is a great deal of curiosity in the infectious disease community as to possible anti-infective links with other chronic diseases such as cardiovascular or neurological disorders. Clinical studies that have studied the effect of azithromycin therapy on the treatment of atherosclerosis have been equivocal, in part, because it has not been convincingly determined whether the Chlamydia pneumoniae in arterial plaque is the causative agent or present as an innocent bystander in a favourable environmental niche [21, 22] . However, if a causal association is proven, a large commercial opportunity awaits the company that can present data from a positive trial with a new antichlamydial agent. Likewise, hints of associations between C. pneumoniae and Alzheimer's disease or asthma [23, 24] suggest that there may be additional chronic illnesses that may ultimately benefit from antibacterial therapy. If these opportunities are developed in the future, this will provide another set of pressures to increase antibacterial resistance, and will provide incentives for companies to identify new organism-specific agents.
Finally, there is now the threat of epidemic outbreaks of resistant organisms in attacks of bioterrorism. Although the mail attacks of anthrax in the USA were fortunately conducted with a highly susceptible Bacillus anthracis strain in 2001 [25] , it is now well established that antibioticresistant strains can be readily selected in vitro [26] , thus leading to the possibility of more resistant strains appearing in the future. Because inhalational anthrax is most frequently a fatal disease due to rapid toxin production, opportunities are available to approach this disease state more creatively, with the development of drugs to attack the toxin itself, in addition to the use of classical antibacterial agents to eradicate the bacteria [27] . And, development of safe and effective vaccines is still an option that is frequently ignored.
Dosing advantages
In addition to a medical need to treat a resistant infection, there can be less obvious medical advantages offered by new agents. Frequency of dosing is one area in which new drugs have made an important difference. An early example was the replacement of ampicillin by amoxicillin because the dosing regimen changed from four times a day to three times a day. Ceftriaxone with once-a-day dosing became a more highly used drug than cefotaxime dosed three times a day, in spite of the fact that cefotaxime was introduced to the market first and had an interchangeable spectrum of activity with ceftriaxone. Also, levofloxacin with once-a-day dosing replaced twice-a-day ciprofloxacin as the leading hospital fluoroquinolone. These changes in dosing regimens can result in higher patient compliance, especially in the outpatient population where once-a-day dosing has become the standard of care. In the hospital setting, reduced dosing frequencies can lead to lower medical costs due to the resources involved in delivering parenteral agents. There also are advantages offered by providing both oral and parenteral agents so that hospitalised patients can be transferred from intravenous (i.v.) therapy to oral therapy on the same drug, and subsequently released from the hospital earlier. These attributes are shared by many of the fluoroquinolones and by linezolid where both oral and i.v. forms are available.
Safety improvements
Improvement in safety can also provide an opportunity for development of a second-or third-inclass agent. Although some adverse events are inherently associated with specific antibiotic classes, the degree to which these manifest can vary greatly. Nephrotoxicity with cephalosporins can be a major problem, with drugs like cephaloridine removed from the market because of their renal toxicity. However, the plethora of 'cephawhatchamacallums' in the 1980s [28] can be attributed to the fact that the newer cephalosporins exhibited good safety profiles with minimal nephrotoxicity when normal doses were given. Fluoroquinolones generally exhibit binding to the hERG ion channel as a class, but the IC 50 values for binding in the patch clamp assay can vary by as much as two orders of magnitude, from 18 lM M for sparfloxacin to 1420 lM M for ofloxacin [29] . Thus, there may be room to improve safety profiles and drug-drug interactions for currently existing antibacterial agents such as linezolid with its reversible monoamine oxidase inhibition [30] and telithromycin with its reversible cytochrome P450 interactions [31] .
D E V E L O P M E N T F A C T O R S

Attractive development opportunities
Development of anti-infective agents offers certain attractions not seen with some other therapeutic areas. Based on historical data through the end of 1999, the probability of an investigational anti-infective agent entering the market was higher than for agents in other therapeutic areas, as shown in Fig. 2 [32] . This advantage is especially notable when success was measured from the first human dose (Phase 1), first patient dose (Phase 2) or first pivotal dose (Phase 3) when anti-infective agents were compared with cardiovascular, oncology or central nervous system (CNS) drugs [33] .
Other historical data indicate that FDA approval times were faster for anti-infective agents compared with drugs in the other therapeutic areas. As seen in Table 3 , during each development phase, anti-infectives had the shortest residency time compared with cardiovascular, NSAIDs and CNS agents [34] . In addition, the capitalised clinical costs per approved NCE were lowest for anti-infective drugs compared with the other therapeutic areas [34] .
Several possible reasons may be cited for the development advantages for anti-infective drugs. First, the drug targets are clearly delineated, with well-established in vitro testing to show that drugs can get to their targets and have the desired therapeutic effect, i.e., killing of the micro-organism. Second, good predictive in vivo efficacy models have been established for a variety of infections caused by specific target organisms, leading to reassurance that clinical trials have a high probability of success. Third, there are clearly defined biomarkers to allow for monitoring of patients in clinical trials. Fourth, the use of pharmacodynamics to predict efficacy, optimal doses, and the potential for resistance selection has become a sophisticated art in the anti-infective area. And fifth, safety issues, especially for hospital-administered drugs, tend to be less than for drugs that are prescribed for chronic illnesses where a patient will take a drug for the rest of his life. Finally, for community drugs with decreased dosing regimens of 3-5 days, long-term safety and follow-up studies lasting for years are generally not required, thereby leading to shorter clinical trials.
Development role for large companies
Large pharmaceutical companies must continue to play a major role in the discovery and development of new anti-infective agents. Companies with active antibacterial research and development programmes currently have the resources and talent to be able to take a drug from the conception stage through to full FDA approval. The basic research scientists in these groups have established resources in terms of financial support and facilities, and have the experience and commitment to follow a drug from identification through to studying clinical isolates for mechanisms of resistance. Development scientists have expertise to run the toxicology and drug metabolism studies, to scaleup compounds under GMP conditions for clinical supplies, and to formulate the agents in pharmacologically acceptable forms. Clinical scientists have experience in running clinical trials, with Anti-infectives  11  14  36  24  Cardiovascular  17  35  39  30  NSAID  21  23  55  39  Neuropharmacological  14  24  41  43 appropriate contacts and clinical sites in place for future studies. And, regulatory groups have experience with the various regulatory agencies so that proper documentation and records are maintained and filed throughout the development process. It is imperative that companies with these sets of experienced investigators maintain a critical mass before this expertise is filtered away into other therapeutic areas. Because many of the same functions are in place for all therapeutic areas, a large company can capitalise on the knowledge from other groups. Shared resources such as scale-up chemistry, formulations, toxicology, metabolism and regulatory groups can work on compounds from any therapeutic area, so dedicated personnel are not lying in wait for the next compound to enter development. Also, because the return on investment may be perceived to be lower for antiinfective drugs [35] , the ability to balance a portfolio with drugs from multiple therapeutic classes means that large companies can afford to stay in less lucrative areas of research such as antibacterial development.
C O M M E R C I A L V I A B I L I T Y Worldwide sales
In addition to the scientific and developmental opportunities in the anti-infectives area, it is still necessary to show that there is a commercial rationale for staying in this area. When worldwide pharmaceutical sales are broken down by therapeutic area, anti-infective agents rank third, behind cardiovascular and CNS drugs (Table 4 ) [36, 37] . The anti-infective market with US $45 bn in sales is further divided into antibacterial, antifungal and antiviral areas (Table 5) , with antibacterial sales providing almost two-thirds of the total revenue [36] . Although other areas of anti-infective drugs have been projected to grow faster than antibacterial agents for the next few years, all sectors show a positive growth rate, with an overall growth of 10% for all anti-infectives.
Interestingly, when the increase in sales is computed in terms of actual dollars, the largest absolute increase in growth is projected for the antibacterial group (Table 5 ). This total represents an increase of $1.7 bn per year. Although companies like to boast about the number of billiondollar drugs in their portfolio, one does not need to introduce a billion-dollar drug every year to be profitable. If a mix of parenteral agents is sold by a single company, sales exceeding $1 bn can be achieved by using the same hospital sales force to market three drugs with sales of $400 m or less.
Over the next 5 years growth in the critical care antibacterial market is projected to increase consistently, based on the increase in antibiotic sales from 1999 to 2002 [38] . This growth can be directly related to the increase in serious infections caused by problem Gram-negative pathogens that are invading the intensive care units of hospitals. It is interesting to note that sales appear to grow for quinolones, carbapenems and new agents, but are projected to decrease or remain steady for the penicillins and cephalosporins. This may reflect the increase in generic agents available in those areas, or the increasing resistance to these agents among Gram-negative pathogens.
C O R P O R A T E R E S P O N S I B I L I T Y Social commitment
Every pharmaceutical company has established a position of social and corporate responsibility to meet the medical needs of its customers. A survey of corporate websites has identified statements of corporate responsibility for virtually every pharmaceutical company in the Western world. These statements, although unique to a specific company, all include many similar expressions such as 'responsibility', 'commitment', 'community', 'values' and 'vision'. However, this corporate responsibility extends beyond internet webpages. Examples of this social commitment include the corporate donations or price-lowering for ivermectin to treat river blindness (Merck), for miconazole for AIDS-affected individuals (Tibotec), and for anti-HIV drugs (GSK) to African populations that cannot afford to pay full price for these agents. Large companies such as AstraZeneca and Johnson & Johnson have demonstrated a social commitment to less profitable research by working on drugs to treat multidrug resistant tuberculosis. All companies exemplify a concern for the welfare of their customers who are constantly looking for new drugs and new treatments to improve their quality of life. However, in the area of anti-infective research, the goal is perhaps one of even greater commitment. The agents that have been developed in the past, and that are being developed for future needs, are not drugs that improve the 'quality of life', but are agents that frequently treat acute, life-threatening diseases.
C O N C L U S I O N S
We need to remember that the antibiotic era began only about 60 years ago at a time when a strep throat could mean a death sentence. Although we have been prolific in the past by developing new antibiotics rapidly, those days are behind us, as so clearly outlined by a number of recent reports, including those from Projan and Shlaes [39] and from Powers [40] in this supplement. With the increasing multidrug resistance that threatens our entire armamentarium of antibiotics, it is imperative that new agents continue to be developed. And, perhaps more importantly, it is critical that large pharmaceutical companies continue to fund basic research to identify the new agents that will be able to circumvent newly emerging mechanisms. There are sound scientific, medical, developmental and commercial reasons for companies to remain in the anti-infective therapeutic area. Although we will always live in a world coinhabited by antibiotic-resistant bacteria, we have a social commitment to devise new approaches to contain them before it is too late.
